Frontlight ResearchEarly access
CompletedPhase 4
Premedication with Intranasal Dexmedetomidine in Sedation of Patients Undergoing Total Knee Arthroplasty
Key facts
- Who runs it
- Turku University Hospital
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 100 people enrolled
- Started
- 10 Jun 2022
- Ended
- 20 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidine
- Placebo
- Record updated
- 22 January 2025
Who can take part
- Age
- 35 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- The patient is scheduled for elective unilateral total knee arthroplasty (TKA) under spinal anesthesia
- Fluent skills in finnish language (to understand the given information and to be able to give informed consent and communicate with the study personnel)
- Age between 35 and 80 years
- Weight between 50 and 100 kg
- American Society of Anesthesiologists status 1-3
- Written informed consent from the patient
Who cannot take part
- A previous history of intolerance to the study drug or related compounds and additives
- Participation in any other study concomitantly or within one month prior to the entry into this study
- Use of any drugs known to cause enzyme induction or inhibition for a period of 30 days prior to the study, use of any natural products (including grapefruit products) for at least 14 days prior to the study and caffeine containing products for at least 24 hours prior to the study. The use of regular doses of paracetamol is allowed
- Disease or condition affecting patient's ability to give written informed consent
- Existing or recent disease possible affecting absorption, distribution, metabolism, excretion or response to the study drug
- History of severe cardiac disease (valvular insufficiency, severe left ventricular dysfunction) or abnormal ECG rhythm (bradycardia < 50/min, 2nd or 3rd degree atrioventricular-block, pacemaker)
- Clinically significant abnormal findings in physical examination or laboratory screening
- Preoperative systolic blood pressure <110 mmHg
- Chronic use of strong opioids, pregabalin, gabapentin, amitriptyline or duloxetine
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to find out if preoperatively given dexmedetomidine is effective analgesic adjuvant for treating postoperative pain in patients undergoing elective total knee arthroplasty (TKA). Another aim is to determine if premedication with intranasal dexmedetomidine could provide sufficient sedation to alleviate anxiety during TKA.
The 2 groups in the trial
- DEX-groupExisting treatment, for comparison
intranasal dexmedetomidine 1 µg/kg
Treatment: Dexmedetomidine
- PLACEBO-groupPlacebo, for comparison
intranasal saline 10 µL/kg
Treatment: Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 January 2025